- CONTACT US
- AFS
- Business
- Bussiness
- Car
- Career
- Celebrity
- Digital Products
- Education
- Entertainment
- Fashion
- Film
- Food
- Fun
- Games
- General Health
- Health
- Health Awareness
- Healthy
- Healthy Lifestyle
- History Facts
- Household Appliances
- Internet
- Investment
- Law
- Lifestyle
- Loans&Mortgages
- Luxury Life Style
- movie
- Music
- Nature
- News
- Opinion
- Pet
- Plant
- Politics
- Recommends
- Science
- Self-care
- services
- Smart Phone
- Sports
- Style
- Technology
- tire
- Travel
- US
- World
Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Lawsuit claims ChatGPT exacerbated man's delusions leading to murder-suicide - 2FDA proposes use of sunscreen ingredient popular in other countries
- 3Ukraine demands army of 800,000 under peace plan
- 4Israel faces tough choices over haredi draft exemptions, legal expert warns
- 5EU states agree first step for Ukraine reparations fund
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
- Wizz CEO: We’re going to invest $1 b. in Israeli market
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- Consumers advised to dispose of 19 cooking pans due to lead leaching risk, FDA reports
- US FDA approves Kura-Kyowa's blood cancer therapy
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- Seven deaths possibly linked to malfunctioning glucose monitors
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
